Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Follicular 22Lymphoma, Mantle-Cell 18Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Non-Hodgkin 10Lymphoma 6Neoplasms 4Lymphoma, B-Cell 4Leukemia, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Neoplasm, Residual 2Leukemia, Hairy Cell 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Indolent Non-Hodgkin's Lymphoma 1Indolent Non-Hodgkin Lymphoma 1Disease 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

blinatumomab 9Cyclophosphamide 7Rituximab 6Lenalidomide 6Dexamethasone 5Azacitidine 5venetoclax 4fludarabine 4Cytarabine 4fludarabine phosphate 3Maintenance 3Busulfan 3tislelizumab 2thymoglobulin 2pembrolizumab 2obinutuzumab 2daratumumab 2Whole-Body Irradiation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Melphalan 2Immunotherapy 2Imatinib Mesylate 2Drug Therapy 2Docetaxel 2Decitabine 2Clofarabine 2Cladribine 2Carboplatin 2Calcium Dobesilate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm, Residual × obinutuzumab × Clear all
NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Weill Medical College of Cornell University

Phase 2 Active not recruiting
37 enrolled 9 charts
Lymphoid

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT02666898 2025-11-26

ICLL07GAI

French Innovative Leukemia Organisation

Phase 2 Completed
135 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡